Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH9056 in Uncontrolled Essential Hypertension
NCT06771245Phase 3Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of valsartan, Levamlodipine in essential hypertension, sponsored by CSPC ZhongQi Pharmaceutical Technology. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
valsartanLevamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06771245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06771245.